The company said its therapy involving cancer drug Keytruda in combination with chemotherapy met the main goal of a late-stage study for treating a type of gastric cancer.
The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.
Advances in immuno-oncology and adaptive cell therapy that began about a decade ago are enabling fresh, biology-driven approaches to bring therapeutic cancer vaccines closer to fruition.
AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.